DeuteRx

0 followers


Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. The team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers.

Industries

Employees

1-10

Links


Org chart

Sheila Dewitt
Chair, President, CEO & Founder
Collapse
Vincent Jacques
SVP Research And Early Development

Board & advisors

Lex Van Der Ploeg
Board & Advisor
Michael Webb
Board & Business Advisor
Tim Barberich
Business Advisor
Laurie Burlingame
Legal Counsel
Kim Drapkin
Financial Advisor
Robert Johnston
Business Advisor
Bruce Maryanoff
R&D Advisor
David Simcox
R&D Advisor